About: The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions
Creator	Kumar, Arun Arora, Bungau, Simona Behl, Tapan Gokhan, Zengin Kaur, Ishnoor Kumar, Chanchal Pal, Giridhari Sahil, Kamal Shrivastava, Gokhan Shrivastava, Kamal Uddin, Sahab Zengin, Sandeep
Source	Elsevier; Medline; PMC
abstract	The novel corona virus disease has shaken the entire world with its deadly effects and rapid transmission rates, posing a significant challenge to the healthcare authorities to develop suitable therapeutic solution to save lives on earth. The review aims to grab the attention of the researchers all over the globe, towards the role of ACE2 in COVID-19 disease. ACE2 serves as a molecular target for the SARS-CoV-2, to enter the target cell, by interacting with the viral glycoprotein spikes. However, the complexity began when numerous studies identified the protective response of ACE2 in abbreviating the harmful effects of vasoconstrictor, anti-inflammatory peptide, angiotensin 2, by mediating its conversion to angiotensin-(1–7), which exercised antagonistic actions to angiotensin 2. Furthermore, certain investigations revealed greater resistance among children as compared to the geriatrics, towards COVID-19 infection, despite the elevated expression of ACE2 in pediatric population. Based upon such evidences, the review demonstrated possible therapeutic interventions, targeting both the protective and deleterious effects of ACE2 in COVID-19 disease, primarily inhibiting ACE2-virus interactions or administering soluble ACE2. Thus, the authors aim to provide an opportunity for the researchers to consider RAAS system to be a significant element in development of suitable treatment regime for COVID-19 pandemic.
has issue date	2020-09-15(xsd:dateTime)
bibo:doi	10.1016/j.lfs.2020.118075
bibo:pmid	32653522
has license	no-cc
sha1sum (hex)	616d7806d2d68ec12bb67cad062988f3d69a3ffb
schema:url	https://doi.org/10.1016/j.lfs.2020.118075
resource representing a document's title	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions
has PubMed Central identifier	PMC7347488
has PubMed identifier	32653522
schema:publication	Life Sci
resource representing a document's body	covid:616d7806d2d68ec12bb67cad062988f3d69a3ffb#body_text
is schema:about of	named entity 'AIMS' named entity 'TRANSMISSION' named entity 'VASOCONSTRICTOR' named entity 'HARMFUL' named entity 'GRAB' named entity 'RAPID' named entity 'N A' named entity 'IDENTIFIED' named entity 'ADMINISTERING' named entity 'LIVES' named entity 'MOLECULAR TARGET' named entity 'ANTIINFLAMMATORY' named entity 'GLOBE' named entity 'SPIKES' covid:arg/616d7806d2d68ec12bb67cad062988f3d69a3ffb named entity 'pediatric' named entity 'geriatrics' named entity 'COVID-19 disease' named entity 'corona virus disease' named entity 'virus' named entity 'glycoprotein' named entity 'antiinflammatory' named entity 'vasoconstrictor' named entity 'angiotensin 2' named entity 'geriatrics' named entity 'pediatrics' named entity 'ACE2' named entity 'coughing' named entity 'ACE2' named entity 'lung' named entity 'anti-inflammatory' named entity 'ACE2' named entity 'innate response' named entity 'hypertensive' named entity 'ACE2' named entity 'transmembrane' named entity 'antioxidant' named entity 'lymphocyte count' named entity 'adaptive immunity' named entity 'COVID' named entity 'infection' named entity 'RAAS' named entity 'metalloproteinase' named entity 'organ' named entity 'cytoplasm' named entity 'ACE inhibitors' named entity 'China' named entity 'angiotensin 2' named entity 'cytokines' named entity 'cluster of differentiation' named entity 'angiotensin' named entity 'ACE2' named entity 'AT1 receptors' named entity 'ACE2' named entity 'open reading frames' named entity 'Russia' named entity 'ACE' named entity 'SARS-CoV' named entity 'angiotensin' named entity 'renin' named entity 'cardiovascular' named entity 'endothelial cells' named entity 'ACE2' named entity 'plasma' named entity 'RAAS' named entity 'glycoprotein' named entity 'renal disorders' named entity 'diabetic nephropathy' named entity 'wild type'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software